168 related articles for article (PubMed ID: 28212550)
1. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival.
Li CF; Liu TT; Chuang IC; Chen YY; Fang FM; Chan TC; Li WS; Huang HY
Oncotarget; 2017 Mar; 8(12):19997-20010. PubMed ID: 28212550
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors.
Li CF; Chuang IC; Liu TT; Chen KC; Chen YY; Fang FM; Li SH; Chen TJ; Yu SC; Lan J; Huang HY
Oncotarget; 2016 Aug; 7(31):49986-49997. PubMed ID: 27366945
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
5. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
6. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
7. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
Rubió-Casadevall J; Borràs JL; Carmona-García MC; Ameijide A; Gonzalez-Vidal A; Ortiz MR; Bosch R; Riu F; Parada D; Martí E; Miró J; Sirvent JJ; Galceran J; Marcos-Gragera R
World J Surg Oncol; 2015 Feb; 13():47. PubMed ID: 25885906
[TBL] [Abstract][Full Text] [Related]
8. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
9. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
[TBL] [Abstract][Full Text] [Related]
10. A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin.
Kondo J; Huh WJ; Franklin JL; Heinrich MC; Rubin BP; Coffey RJ
J Pathol; 2020 Dec; 252(4):441-450. PubMed ID: 32944951
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors.
Guenat D; Deroo O; Magnin S; Chaigneau L; Monnien F; Borg C; Mougin C; Emile JF; Prétet JL
Oncol Rep; 2017 Mar; 37(3):1671-1681. PubMed ID: 28098915
[TBL] [Abstract][Full Text] [Related]
12. Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location.
Wei YC; Li CF; Yu SC; Chou FF; Fang FM; Eng HL; Uen YH; Tian YF; Wu JM; Li SH; Huang WW; Li WM; Huang HY
Mod Pathol; 2009 Oct; 22(10):1351-60. PubMed ID: 19648886
[TBL] [Abstract][Full Text] [Related]
13. AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Li CF; Chen LT; Lan J; Chou FF; Lin CY; Chen YY; Chen TJ; Li SH; Yu SC; Fang FM; Tai HC; Huang HY
Oncotarget; 2014 Nov; 5(22):11588-603. PubMed ID: 25473890
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
15. Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST.
Urbini M; Indio V; Tarantino G; Ravegnini G; Angelini S; Nannini M; Saponara M; Santini D; Ceccarelli C; Fiorentino M; Vincenzi B; Fumagalli E; Casali PG; Grignani G; Pession A; Ardizzoni A; Astolfi A; Pantaleo MA
Genes Chromosomes Cancer; 2019 Sep; 58(9):636-642. PubMed ID: 30887595
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
17. The rs17084733 variant in the
Ravegnini G; Serrano C; Simeon V; Sammarini G; Nannini M; Roversi E; Urbini M; Ferrè F; Ricci R; Tarantino G; Pantaleo MA; Hrelia P; Angelini S
Epigenetics; 2019 Jun; 14(6):545-557. PubMed ID: 30983504
[TBL] [Abstract][Full Text] [Related]
18. Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors.
Li CF; Liu TT; Wang JC; Yu SC; Chen YY; Fang FM; Li WS; Huang HY
J Clin Med; 2018 Nov; 7(11):. PubMed ID: 30388854
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.
Li CF; Huang WW; Wu JM; Yu SC; Hu TH; Uen YH; Tian YF; Lin CN; Lu D; Fang FM; Huang HY
Clin Cancer Res; 2008 Dec; 14(23):7822-31. PubMed ID: 19047110
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors.
Schoppmann SF; Ricken G; Ilhan-Mutlu A; Nirtl N; Streubel B; Preusser M; Birner P
Cancer Invest; 2014 Aug; 32(7):363-7. PubMed ID: 24897389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
